Open letter to AbbVie to make glecaprevir/pibrentasvir (G/P) accessible for people with hepatitis C
MSF Access Campaign sent an open letter to pharmaceutical corporation AbbVie, urging them to make the medicine glecaprevir/pibrentasvir (G/P) more accessible to treat people with hepatitis C in low- and middle-income countries (LMICs), including in MSF programmes.
Since 2018, MSF has made numerous requests to AbbVie to enable the procurement of G/P. But this lifesaving treatment continues to remain out of reach for many people with hepatitis C in LMICs.
MSF calls on AbbVie to:
- Establish a compassionate use program for people for whom other regimens have failed, in all LMICs where G/P remains unregistered and unavailable.
- Expedite registration of G/P in LMICs.
- Offer G/P at an affordable price for people in MSF’s programmes in Pakistan and people in LMICs.
- Expand the territory of the G/P voluntary licensing agreement with the Medicines Patent Pool (MPP) to ensure generic companies have sufficient incentive to develop and supply this essential treatment.